iCAD’s “ProFound Insights, ProFound Impact” Webinar Series to Highlight ProFound AI Risk
Leading experts, including distinguished
researchers from the Karolinska Institutet and clinicians using it in daily
practice, to discuss significant impact and value of technology
NASHUA, N.H. – June 7, 2022 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing
innovative cancer detection and therapy solutions, today announced that its
next webinar, titled “Risk Assessment Reimagined,” will feature leading
experts who will discuss the significant impact of ProFound AI® Risk for
Digital Breast Tomosynthesis (DBT), including distinguished researchers
from the Karolinska Institutet who assisted in the development of the technology
and clinicians who are using it in daily practice. Part of iCAD’s “ProFound Insights, ProFound Impact” webinar series, the live
event will feature iCAD’s Product Director of AI Solutions, Andjela Azabagic as
moderator and will take place on Tuesday, June 21 at 10 am PT/1 pm ET/7
pm CEST.Visit this
link to register.
ProFound AI Risk is the world’s
first clinical decision support tool that identifies women at high risk of
developing cancer before or at their next screening. New research supporting
ProFound AI Risk was recently published
in the peer-reviewed journal, Science
Translational Medicine.[i] According to study findings,
ProFound AI Risk for DBT offers up to 2.4 times more accuracy than traditional
lifetime risk models.i
The event’s panel will include two
authors of this study, who will discuss this research in more detail:
- Mikael Eriksson, PhD, Medical Epidemiology and
Biostatistics, Karolinska Institutet, Stockholm, Sweden - Per
Hall, MD, PhD, Professor/Senior Physician, Karolinska Institutet and Södersjukhuset,
Stockholm, Sweden
Additional panelists include distinguished
radiologists, who are using iCAD’s Breast AI suite, including ProFound AI Risk,
in daily practice:
- Axel Gräwingholt, MD, Radiologie am Theater,
Paderborn, Germany - Mark Traill, MD, University of Michigan
Health-West, Wyoming, Michigan
Hear from the event’s featured panelists:
“ProFound AI Risk offers the
potential to aid radiologists in refining personalizing screening
recommendations and discussing risk with women, which could in turn influence
their screening regimen compliance and potentially lead to earlier detection,
reduced treatment costs and improved outcomes. ProFound AI Risk is the first
model that identifies women not only being at high risk but more likely to
present with later stage tumors than early-stage cancers. It is known that
breast cancer survival is four and 12-fold worse for stage II and III cancers
compared to stage 0 and I cancers in the first four years after diagnosis.
Furthermore, the treatment cost for stage II and III cancers is more than twice
that of stage 0 and I cancers in the first 24 months after diagnosis.”
-Mikael Eriksson, PhD, Medical
Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
“Our algorithm is designed to
provide physicians with information about a woman’s short-term risk of being
diagnosed with breast cancer, so that they may further personalize her
screening and surveillance plan. This may include screening frequency
adjustment, supplemental imaging, genetic testing and/or risk reduction
strategies. Ultimately, the goal of this technology is to enhance efficiency
for clinicians and improve outcomes for patients through earlier detection.”
-Per Hall, MD, PhD, Professor/Senior Physician, Karolinska
Institutet and Södersjukhuset,
Stockholm, Sweden
“ProFound AI Risk is a powerful
tool that may aid in the detection of interval cancers, or lesions that are
detected between routine mammography screenings. In my experience using the
technology, I have found it offers valuable insights for clinicians who may be
looking to provide a stratified risk assessment for patients, and is easy to
use compared to other breast cancer risk models.”
-Axel
Gräwingholt, MD, Radiologie am Theater, Paderborn, Germany
“AI is revolutionizing many facets
of healthcare, including breast cancer screening, particularly as DBT grows in
adoption and the medical community continues to discover the importance of
breast density assessments and risk stratification in breast cancer screening.
Only iCAD’s portfolio of breast health solutions offers the ability to provide
clinicians with a broader view of each individual patient’s case, along with
her breast density and short-term risk, empowering clinicians with crucial
information that can help them tailor screening regimens for women based on
their individual risk.”
-Mark
Traill, MD, University of Michigan Health-West
iCAD’s “ProFound Insights, ProFound Impact” webinar series launched
earlier this year, featuring distinguished clinical, IT and administrative
experts, customer success stories and impactful case studies. Previous event recordings are available
on the Company’s website, www.icadmed.com.
About iCAD, Inc.
Headquartered in
Nashua, NH, iCAD® is a global medical technology leader providing innovative
cancer detection and therapy solutions. For more information, visit www.icadmed.com.
Forward-Looking Statements
Certain statements contained in this News Release constitute
“forward-looking statements” within the meaning of the Private Securities
Litigation Reform Act of 1995, including statements about the expected benefits
of ProFound AI®, the benefits of the Company’s products, and future prospects
for the Company’s technology platforms and products. Such forward-looking
statements involve a number of known and unknown risks, uncertainties and other
factors which may cause the actual results, performance, or achievements of the
Company to be materially different from any future results, performance, or
achievements expressed or implied by such forward-looking statements. Such
factors include, but are not limited, to the Company’s ability to achieve
business and strategic objectives, the willingness of patients to undergo
mammography screening in light of risks of potential exposure to Covid-19,
whether mammography screening will be treated as an essential procedure,
whether ProFound AI will improve reading efficiency, improve specificity and
sensitivity, reduce false positives and otherwise prove to be more beneficial
for patients and clinicians, the impact of supply and manufacturing constraints
or difficulties on our ability to fulfill our orders, uncertainty of future sales
levels, to defend itself in litigation matters, protection of patents and other
proprietary rights, product market acceptance, possible technological
obsolescence of products, increased competition, government regulation, changes
in Medicare or other reimbursement policies, risks relating to our existing and
future debt obligations, competitive factors, the effects of a decline in the
economy or markets served by the Company; and other risks detailed in the
Company’s filings with the Securities and Exchange Commission. The words
“believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,”
“anticipate,” “likely,” “seek,” and similar expressions identify
forward-looking statements. Readers are cautioned not to place undue reliance
on those forward-looking statements, which speak only as of the date the
statement was made. The Company is under no obligation to provide any updates
to any information contained in this release. For additional disclosure
regarding these and other risks faced by iCAD, please see the disclosure
contained in our public filings with the Securities and Exchange Commission,
available on the Investors section of our website at http://www.icadmed.com and
on the SEC’s website at http://www.sec.gov.
Contact:
Media Inquiries:
Jessica
Burns, iCAD
+1-201-423-4492
Investor
Inquiries:
iCAD
Investor Relations
[i] Eriksson,
M et al. A risk model for digital breast tomosynthesis to predict breast cancer
and guide clinical care. Science Translational Medicine. 14 (644). 2022 May 11.
Accessed via DOI: 10.1126/scitranslmed.abn3971.